Loading company…
Topos Bio uses an AI platform to study intrinsically disordered proteins for drug discovery.
Topos Bio develops an AI platform focused on intrinsically disordered proteins linked to diseases such as Alzheimer's and prostate cancer. Its Topos-1 model generates conformational ensembles to help researchers study protein dynamics and drug targets. Based in San Francisco, the company raised USD 10.5 mn in Seed funding in January 2026, co-led by Boldstart Ventures, Threshold Ventures and Neo Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in